Ping LI
1,2*
Ziyi Jiang
2
Jingjing SHI
2
Zihang Yu
2
Yan Zhao
1
Sanyang Han
2*
Lan Ma
1,2*The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1530364
This article is part of the Research Topic Decoding Tumor Plasticity: Integrative Analysis of Epigenetic Regulation and Microenvironmental Adaptation View all 9 articles
A self-assembled nanoparticle vaccine elicits potent neutralizing antibody response against EBV infection
Provisionally accepted- 1 Shenzhen Bay Laboratory, Shenzhen, China
- 2 Shenzhen International Graduate School, Tsinghua University, Shenzhen, Guangdong Province, China
Background: Epstein-Barr virus (EBV) is a significant global public health concern for its high associations with various malignancies and autoimmune diseases. Over 90% of global population is chronically infected by EBV, impacting numerous cancer-related cases annually. However, none of effective prophylactic vaccines against EBV is approved at present.In this study, we developed a novel vaccine candidate based on epitope peptides from the receptor binding domain of EBV-encoded gp350 glycoprotein to prevent EBV infection. These epitope peptides were detected the binding capability with host cells, and then fused by flexibility linkers and expressed in Escherichia coli to reduce the unnecessary glycan modifications to simulate their free-glycan status. The fused recombinant protein (L350) was displayed on the surface of ferritin-based nanoparticle. The immunogenicity of the L350-Ferritin nanoparticle was evaluated in Balb/c mice. And the neutralizing titers of sera from immunized mice were detected by infection blocking assay in a vitro cell model.Results: All the 5 epitope peptides could bind to AKATA cells and their fused recombinant protein (L350) was successfully presented on the surface of self-assembled ferritin nanoparticles. Sera from L350-Ferritin nanoparticle immunized mice showed high titer of both L350 protein-specific and gp350D123 protein-specific antibodies. And sera from gp350D123 protein immunized mice could also recognize L350 protein well. Most importantly, L350-Ferritin nanoparticle induced efficient neutralizing antibodies to block EBV-GFP infection in AKATA cells, and also constructed a strong antigen-specific B cell memory in immunized mice. Moreover, histopathological changes of main tissues from all vaccinated mice were not observed.These data indicate that the L350-Ferritin nanoparticle vaccine candidate has considerable potential application in preventing EBV infection, and provide a promising basis for developing prophylactic EBV vaccines.
Keywords: Epstein-Barr virus (EBV), Vaccine, epitope, ferritin, nanoparticle
Received: 18 Nov 2024; Accepted: 05 Dec 2024.
Copyright: © 2024 LI, Jiang, SHI, Yu, Zhao, Han and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ping LI, Shenzhen Bay Laboratory, Shenzhen, China
Sanyang Han, Shenzhen International Graduate School, Tsinghua University, Shenzhen, 518055, Guangdong Province, China
Lan Ma, Shenzhen International Graduate School, Tsinghua University, Shenzhen, 518055, Guangdong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.